These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 28741382)

  • 41. Differentiating sodium-glucose co-transporter-2 inhibitors in development for the treatment of type 2 diabetes mellitus.
    Washburn WN; Poucher SM
    Expert Opin Investig Drugs; 2013 Apr; 22(4):463-86. PubMed ID: 23452053
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A safety evaluation of canagliflozin : a first-in-class treatment for type 2 diabetes.
    Boyle LD; Wilding JP
    Expert Opin Drug Saf; 2014 Nov; 13(11):1535-44. PubMed ID: 25340618
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Luseogliflozin reduces epicardial fat accumulation in patients with type 2 diabetes: a pilot study.
    Bouchi R; Terashima M; Sasahara Y; Asakawa M; Fukuda T; Takeuchi T; Nakano Y; Murakami M; Minami I; Izumiyama H; Hashimoto K; Yoshimoto T; Ogawa Y
    Cardiovasc Diabetol; 2017 Mar; 16(1):32. PubMed ID: 28253918
    [TBL] [Abstract][Full Text] [Related]  

  • 44. An evidence-based practice-oriented review focusing on canagliflozin in the management of type 2 diabetes.
    Messana JA; Schwartz SS; Townsend RR
    Vasc Health Risk Manag; 2017; 13():43-54. PubMed ID: 28255241
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Characterization and comparison of SGLT2 inhibitors: Part 3. Effects on diabetic complications in type 2 diabetic mice.
    Tahara A; Takasu T; Yokono M; Imamura M; Kurosaki E
    Eur J Pharmacol; 2017 Aug; 809():163-171. PubMed ID: 28506912
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Hypoxia-inducible factor-1α is the therapeutic target of the SGLT2 inhibitor for diabetic nephropathy.
    Bessho R; Takiyama Y; Takiyama T; Kitsunai H; Takeda Y; Sakagami H; Ota T
    Sci Rep; 2019 Oct; 9(1):14754. PubMed ID: 31611596
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [SGLT2 inhibitor (Luseogliflozin): a new mechanism for treating type 2 diabetes mellitus and therapeutic potential to prevent the progression of diabetic complications].
    Kojima N; Samukawa Y; Takahashi T
    Nihon Yakurigaku Zasshi; 2016; 148(5):253-258. PubMed ID: 27803438
    [No Abstract]   [Full Text] [Related]  

  • 48. Effects of diuretics on sodium-dependent glucose cotransporter 2 inhibitor-induced changes in blood pressure in obese rats suffering from the metabolic syndrome.
    Rahman A; Kittikulsuth W; Fujisawa Y; Sufiun A; Rafiq K; Hitomi H; Nakano D; Sohara E; Uchida S; Nishiyama A
    J Hypertens; 2016 May; 34(5):893-906. PubMed ID: 26982381
    [TBL] [Abstract][Full Text] [Related]  

  • 49. SGLT2 inhibitors: a new emerging therapeutic class in the treatment of type 2 diabetes mellitus.
    Ghosh RK; Ghosh SM; Chawla S; Jasdanwala SA
    J Clin Pharmacol; 2012 Apr; 52(4):457-63. PubMed ID: 21543663
    [TBL] [Abstract][Full Text] [Related]  

  • 50. In vitro evaluation of potential drug interactions mediated by cytochrome P450 and transporters for luseogliflozin, an SGLT2 inhibitor.
    Chino Y; Hasegawa M; Fukasawa Y; Mano Y; Bando K; Miyata A; Nakai Y; Endo H; Yamaguchi JI
    Xenobiotica; 2017 Apr; 47(4):314-323. PubMed ID: 27324291
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Renal sodium-glucose cotransporter inhibition in the management of type 2 diabetes mellitus.
    Abdul-Ghani MA; Norton L; DeFronzo RA
    Am J Physiol Renal Physiol; 2015 Dec; 309(11):F889-900. PubMed ID: 26354881
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The Role of the Kidney and SGLT2 Inhibitors in Type 2 Diabetes.
    Katz PM; Leiter LA
    Can J Diabetes; 2015 Dec; 39 Suppl 5():S167-75. PubMed ID: 26654860
    [TBL] [Abstract][Full Text] [Related]  

  • 53. SGLT2 inhibitors to control glycemia in type 2 diabetes mellitus: a new approach to an old problem.
    Jabbour SA
    Postgrad Med; 2014 Jan; 126(1):111-7. PubMed ID: 24393758
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Sodium Glucose Co-transporter Type 2 (SGLT2) Inhibitors in CKD].
    Insalaco M; Zanoli L; Rastelli S; Lentini P; Rapisarda F; Fatuzzo P; Castellino P; Granata A
    G Ital Nefrol; 2015; 32(4):. PubMed ID: 26252258
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Preclinical metabolism and disposition of luseogliflozin, a novel antihyperglycemic agent.
    Hasegawa M; Chino Y; Horiuchi N; Hachiuma K; Ishida M; Fukasawa Y; Nakai Y; Yamaguchi J
    Xenobiotica; 2015; 45(12):1105-15. PubMed ID: 26489961
    [TBL] [Abstract][Full Text] [Related]  

  • 56. SGLT2 inhibitors: a promising new therapeutic option for treatment of type 2 diabetes mellitus.
    Misra M
    J Pharm Pharmacol; 2013 Mar; 65(3):317-27. PubMed ID: 23356840
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Canagliflozin: a sodium glucose co-transporter 2 inhibitor for the treatment of type 2 diabetes mellitus.
    Rosenthal N; Meininger G; Ways K; Polidori D; Desai M; Qiu R; Alba M; Vercruysse F; Balis D; Shaw W; Edwards R; Bull S; Di Prospero N; Sha S; Rothenberg P; Canovatchel W; Demarest K
    Ann N Y Acad Sci; 2015 Nov; 1358():28-43. PubMed ID: 26305874
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Emerging sodium/glucose co-transporter 2 inhibitors for type 2 diabetes.
    Boyle LD; Wilding JP
    Expert Opin Emerg Drugs; 2013 Sep; 18(3):375-91. PubMed ID: 23968378
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences.
    Gallo LA; Wright EM; Vallon V
    Diab Vasc Dis Res; 2015 Mar; 12(2):78-89. PubMed ID: 25616707
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Adverse events with sodium-glucose co-transporter-2 inhibitors: A global analysis of international spontaneous reporting systems.
    Raschi E; Parisotto M; Forcesi E; La Placa M; Marchesini G; De Ponti F; Poluzzi E
    Nutr Metab Cardiovasc Dis; 2017 Dec; 27(12):1098-1107. PubMed ID: 29174026
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.